deltatrials
Terminated PHASE1 NCT00447122

BrUOG-PA-209: Lapatinib and Gemcitabine for Metastatic Pancreaticobiliary Cancer

BrUOG-PA-209: Lapatinib and Gemcitabine for Metastatic Pancreaticobiliary Cancer: A Phase I Study #108181

Sponsor: Brown University

Conditions Metastatic Pancreatic Cancer
Interventions Gemcitabine 1000mg/m2 100minutes Gemcitabine 1000mg/m2 30 minutes Lapatinib 1000mg/d Lapatinib 1500mg/d Oxaliplatin 100mg/m2
Updated 7 times since 2017 Last updated: Jan 5, 2022 Started: Mar 31, 2007 Primary completion: Aug 31, 2008 Completion: Aug 31, 2008

Listed as NCT00447122, this PHASE1 trial focuses on Metastatic Pancreatic Cancer and remains terminated or withdrawn. Sponsored by Brown University, it has been updated 7 times since 2007, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Change History

7 versions recorded

  1. Sep 2024 — Present [monthly]

    Terminated PHASE1

  2. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE1

  3. Apr 2022 — Jul 2024 [monthly]

    Terminated PHASE1

    Phase: PHASE2 → PHASE1

  4. Jan 2021 — Apr 2022 [monthly]

    Terminated PHASE2

  5. Jun 2018 — Jan 2021 [monthly]

    Terminated PHASE2

▶ Show 2 earlier versions

  1. Feb 2017 — Jun 2018 [monthly]

    Terminated PHASE2

  2. Jan 2017 — Feb 2017 [monthly]

    Terminated PHASE2

    First recorded

Mar 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Brown University
  • Memorial Hospital of Rhode Island
  • Rhode Island Hospital
  • The Miriam Hospital
Data source: Brown University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Providence, United States